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Abstract: PURPOSE: Transplantation of pigmented tissue-engineered human autologous skin substitutes
represents a promising procedure to cover skin defects. We have already demonstrated that we can
restore the patient’s native light or dark skin color by adding melanocytes to our dermo-epidermal skin
analogs. In this long-term study, we investigated if melanocytes in our skin substitutes continue to
express markers as BCL2, SOX9, and MITF, known to be involved in survival, differentiation, and
function of melanocytes. METHODS: Human epidermal melanocytes and keratinocytes, as well as dermal
fibroblasts from light- and dark-pigmented skin biopsies were isolated and cultured. Bovine collagen
hydrogels containing fibroblasts were prepared, and melanocytes and keratinocytes were seeded in a 1:5
ratio onto the gels. Pigmented dermo-epidermal skin substitutes were transplanted onto full-thickness
wounds of immuno-incompetent rats and analyzed for the expression of melanocyte markers after 15
weeks. RESULTS: Employing immunofluorescence staining techniques, we observed that our light and
dark dermo-epidermal skin substitutes expressed the same typical melanocyte markers including BCL2,
SOX9, and MITF 15 weeks after transplantation as normal human light and dark skin. CONCLUSIONS:
These data suggest that, even in the long run, our light and dark dermo-epidermal tissue-engineered
skin substitutes contain melanocytes that display a characteristic expression pattern as seen in normal
pigmented human skin. These findings have crucial clinical implications as such grafts transplanted onto
patients should warrant physiological numbers, distribution, and function of melanocytes.
DOI: https://doi.org/10.1007/s00383-014-3622-7





Biedermann, Thomas; Klar, Agnieszka S; Böttcher-Haberzeth, Sophie; Michalczyk, Teresa; Schiestl,
Clemens; Reichmann, Ernst; Meuli, Martin (2015). Long-term expression pattern of melanocyte mark-




Long-term expression pattern of melanocyte markers
in light- and dark-pigmented dermo-epidermal cultured
human skin substitutes
Thomas Biedermann • Agnieszka S. Klar • Sophie Böttcher-Haberzeth •
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Abstract
Purpose Transplantation of pigmented tissue-engineered
human autologous skin substitutes represents a promising
procedure to cover skin defects. We have already demon-
strated that we can restore the patient’s native light or dark
skin color by adding melanocytes to our dermo-epidermal
skin analogs. In this long-term study, we investigated if
melanocytes in our skin substitutes continue to express
markers as BCL2, SOX9, and MITF, known to be involved
in survival, differentiation, and function of melanocytes.
Methods Human epidermal melanocytes and keratino-
cytes, as well as dermal fibroblasts from light- and dark-
pigmented skin biopsies were isolated and cultured. Bovine
collagen hydrogels containing fibroblasts were prepared,
and melanocytes and keratinocytes were seeded in a 1:5
ratio onto the gels. Pigmented dermo-epidermal skin sub-
stitutes were transplanted onto full-thickness wounds of
immuno-incompetent rats and analyzed for the expression
of melanocyte markers after 15 weeks.
Results Employing immunofluorescence staining tech-
niques, we observed that our light and dark dermo-epi-
dermal skin substitutes expressed the same typical
melanocyte markers including BCL2, SOX9, and MITF
15 weeks after transplantation as normal human light and
dark skin.
Conclusions These data suggest that, even in the long
run, our light and dark dermo-epidermal tissue-engineered
skin substitutes contain melanocytes that display a char-
acteristic expression pattern as seen in normal pigmented
human skin. These findings have crucial clinical implica-
tions as such grafts transplanted onto patients should
warrant physiological numbers, distribution, and function
of melanocytes.
Keywords Melanocytes  Human pigmented
dermo-epidermal skin substitutes  Tissue engineering
Introduction
The application of split-thickness skin grafts still is the
standard method to cover full-thickness skin defects
resulting from excisions of large burn injuries, scar revi-
sions, and giant congenital nevi [1, 2]. Obviously, the use
of split-thickness skin is limited by the amount of donor
sites available.
Laboratory cultured epidermal autografts (CEA) con-
sisting of only keratinocytes were the first tissue engi-
neering attempts to overcome this limitation and to provide
enough autologous skin for the patient [3]. Often, the
functional and esthetic outcomes after CEA application
were unsatisfying [4]. To improve tissue-engineered skin,
dermo-epidermal skin substitutes were introduced, con-
taining epithelial cells and mesenchymal fibroblasts [5].
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Over the last 15 years, we have been developing dermo-
epidermal skin substitutes with the goal to produce large,
near-natural skin analogs to be applied clinically [6, 7]. In
particular, we wanted to integrate melanocytes in our
dermo-epidermal skin substitutes to produce physiologi-
cally pigmented constructs. Clearly, the absence or irreg-
ular distribution of melanocytes in skin substitutes makes
the skin vulnerable with regard to UV irradiation and leads
to disfiguring hypo- or hyperpigmented patches after
transplantation [8].
We recently described the fabrication of such light- and
dark-pigmented dermo-epidermal skin substitutes consist-
ing of human keratinocytes, melanocytes, and fibroblasts
[9]. These skin substitutes were transplanted in a long-term
assay for 15 weeks and displayed the same light or dark
skin color as the donor skin.
In the present experimental study, we wanted to inves-
tigate the presence and the expression pattern of typical
described melanocyte markers in our pigmented dermo-
epidermal skin substitutes (pigmentDESS) that are known
to be involved in melanocyte survival, proliferation, dif-
ferentiation, and function.
Materials and methods
Shortly, we transplanted light and dark pigmentDESS
containing human epidermal melanocytes and keratino-
cytes, as well as dermal fibroblasts, isolated and cultured
from light (Fitzpatrick skin type I–II) and dark (Fitzpatrick
skin type V) skin samples. 15 weeks after transplantation,
we investigated the pigmentDESS for the expression of the
anti-apoptotic marker BCL2, the pigmentation-regulating
factors SOX9 and MITF, and the survival and differentia-
tion marker SOX10.
Human skin specimens
The study was conducted according to the Declaration of
Helsinki and with permission by the Ethic Commission of
the Canton Zurich. Informed consent for skin sampling was
given by parents or patients. Human foreskin samples from
patients ranging in age between one and 16 years were
used.
Isolation and culturing of primary human cells
The cells were isolated from light (Fitzpatrick skin type
I–II) and dark (Fitzpatrick skin type V) foreskin samples.
Keratinocytes and fibroblasts were isolated and cultured as
described in Pontiggia et al. [10], and melanocytes as
specified in Böttcher-Haberzeth et al. [11].
Preparation of pigmentDESS
PigmentDESS were prepared as described in Biedermann
et al. [12]. In brief, as a dermal portion, collagen type I was
casted in 6-well cell culture inserts with 3.0 lm pore-size
membranes (BD Falcon, Switzerland). Rat tail collagen
type I (0.7 ml) (BD Biosciences, Switzerland) was mixed
with 0.2 ml chilled neutralization buffer containing 0.15 M
NaOH and 1 9 105 fibroblasts (passage 2). After gel
polymerization (10 min at room temperature, and 20 min at
37 C), the dermal equivalents were cultured in DMEM/
10 %FCS (Invitrogen, Switzerland) for 5 days. Subse-
quently, human keratinocytes and melanocytes (ratio 5:1,
passages 2–3) were seeded onto the dermal equivalent at a
density of 5 9 105 cells. The pigmentDESS were cultured
in SFM (Invitrogen, Switzerland) for 1 week before trans-
plantation. The medium was changed every second day.
Transplantation of cultured pigmentDESS
The surgical protocol was approved by the local Committee
for Experimental Animal Research (permission number
76/2011). Immuno-incompetent female nu/nu rats,
8–10 weeks old (Charles River, Germany), were prepared
and anesthetized as previously described [13]. As protection
of the pigmentDESS and as prevention from wound closure
by the rat skin, custom-made surgical steel rings (diameter
2.6 cm) were sutured into full-thickness skin defects cre-
ated on the backs of the rats, using non-absorbable polyester
sutures (Ethibond, Ethicon, USA). The transplants were
then covered with a silicone foil (Silon-SES, BMS, USA), a
polyurethane sponge (Ligasano, Ligamed, Austria), and a
tape (Leukoplast, BSN medical, Germany) as wound
dressing. Dressing changes were performed once per week.
Analyses of transplanted pigmentDESS
The pigmentDESS were excised 15 weeks after trans-
plantation and processed for paraffin or cryo-embedding.
Immunohistochemical analysis was performed as
described by Kiowski et al. [14]. Paraffin sections (5 lm)
were deparaffinized in xylene and rehydrated. For antigen
retrieval, slides were heated with cell conditioner 1 (Ven-
tana Medical Systems, Tucson, AZ). Sections were stained
with the following antibodies: MITF (clone 5þD5, 1:50,
Abcam, Germany) and SOX10 (clone N-20, 1:50, Santa
Cruz, USA). The antibody binding was visualized using
detection kits (iVIEW DAB detection and ultraView Uni-
versal Alkaline Phosphatase Red Detection kits, Ventana,
Switzerland). Slides were counterstained with hematoxylin.
Cryosections were stained according to Biedermann
et al. [15]. The following antibodies were used: HMB45,
(clone HMB45, 1:50, Dako, Germany), BCL2, 1:50, clone
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124, Abnova, Germany), SOX9 (clone 3C10, 1:50, Abcam,
Germany).
Pictures of immunofluorescence stainings were taken
with a DXM1200F digital camera connected to a Nikon
Eclipse TE2000-U inverted microscope. The device is
equipped with Hoechst 33342, FITC, and TRITC filter sets
(Nikon AG, Switzerland; Software: Nikon ACT-1 vers.
2.70). Images were processed with Photoshop 11.0 (Adobe
Systems Inc, Germany).
Results
Expression of BCL2 in transplanted pigmentDESS
The pigmentDESS were analyzed 15 weeks after trans-
plantation for the presence and the expression pattern of the
mitochondrial anti-apoptotic marker BCL2 in the epider-
mis. In light and dark pigmentDESS, BCL2 (green) was
expressed in a comparable manner (Fig. 1a–f). In both
Fig. 1 Expression pattern of BCL2 in pigmentDESS and normal
human skin. Expression of BCL2 (green) and HMB45 (red) in light
pigmentDESS 15 weeks after transplantation. a Expression of BCL2
is restricted to the basal layer of the epidermis. b Expression pattern
without a nuclei counterstaining for better overview. c A magnifica-
tion of the white dotted square in b highlighting the co-expression of
BCL2 and HMB45 (white arrow) in epidermal melanocytes. Expres-
sion of BCL2 (green) and HMB45 (red) in dark pigmentDESS
15 weeks after transplantation d with and e without nuclear count-
erstaining. f Highlighting the co-expression of BCL2 and HMB45
(white arrow) in epidermal melanocytes. Expression of BCL2 (green)
and HMB45 (red) in dark human skin g with and h without nuclear
counterstaining. i Highlighting the co-expression of BCL2 and
HMB45 (white arrow) in epidermal melanocytes. Expression of
BCL2 (green) and HMB45 (red) in light human skin j with and
k without nuclear counterstaining. l Highlighting the co-expression of
BCL2 and HMB45 (white arrow) in epidermal melanocytes. Cell
nuclei are stained with Hoechst (blue). Scale bars a, b, d, e, g, h, j,
k 100 lm and c, f, i, l 20 lm
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types of DESS, the BCL2 expression was restricted to the
basal layer of the epidermis. To confirm the presence of
BCL2 in epidermal melanocytes, a staining against the
melanocyte-specific marker HMB45 (red, Fig. 1a–f) was
applied. The double staining without cell nuclei counter-
staining for light (Fig. 1b) and dark (Fig. 1e) pigmentDESS
Fig. 2 Expression pattern of SOX9 in pigmentDESS and normal
human skin. Expression of SOX9 (green) and HMB45 (red) in light
pigmentDESS 15 weeks after transplantation. a Expression of
HMB45 (red) is seen in melanocytes of the basal layer of the
epidermis. b Displaying the expression pattern without a nuclei
counterstaining showing the expression of SOX9 in keratinocytes in
all layers of the epidermis and in melanocytes in the basal layer of the
epidermis. c is a magnification of the white dotted square in
b highlighting the co-expression of SOX9 and HMB45 (white arrow)
in epidermal melanocytes. Expression of SOX9 (green) and HMB45
(red) in dark pigmentDESS 15 weeks after transplantation d with and
e without nuclear counterstaining. f Highlighting the co-expression of
SOX9 and HMB45 (white arrow) in epidermal melanocytes. Expres-
sion of SOX9 (green) and HMB45 (red) in dark human skin g with
and h without nuclear counterstaining. i Highlighting the co-
expression of SOX9 and HMB45 (white arrow) in epidermal
melanocytes. Expression of SOX9 (green) and HMB45 (red) in light
human skin j with and k without nuclear counterstaining. l Highlight-
ing the co-expression of SOX9 and HMB45 (white arrow) in
epidermal melanocytes. Cell nuclei are stained with Hoechst (blue).
Scale bars a, b, d, e, g, h, j, k 100 lm and c, f, i, l 20 lm
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is shown for better overview. The white arrows in Fig. 1c
and f (higher magnifications of the white squares in Fig. 1b
and e) indicate melanocytes double positive for BCL2 and
HMB45.
For comparison, dark and light normal human skin was
stained for BCL2 (green) and HMB45 (red) (Fig. 1g–l).
BCL2-expressing cells were detected in the basal layer of
the epidermis in dark and light skin (Fig. 1h, k). In a higher
magnification, BCL2 and HMB45 double-positive mela-
nocytes are shown (Fig. 1i, l, white arrows).
Expression of SOX9 in transplanted pigmentDESS
The transplanted pigmentDESS were also analyzed
regarding the presence and expression pattern of the
nuclear transcription factor SOX9 in the epidermis. In light
and dark pigmentDESS, SOX9 (green) was expressed
throughout the cells in the epidermis in a comparable
manner (Fig. 2a–f). To confirm the presence of SOX9 in
melanocytes, the double staining with HMB45 and without
cell nuclei counterstaining for light (Fig. 2b) and dark
(Fig. 2e) pigmentDESS is shown for better overview. A
higher magnification thereof is shown in Fig. 2c and f;
white arrows point at melanocytes double positive for
SOX9 and HMB45, confirming the expression of SOX9 in
melanocytes.
Dark and light normal human skin was stained for
SOX9 and HMB45 (Fig. 2g–l) for comparison. SOX9 was
expressed in all the cells of the epidermis in dark and
light skin. In a higher magnification, SOX9 and HMB45
double-positive melanocytes are shown (Fig. 2i, l, white
arrows).
Expression of SOX10 and MITF in transplanted
pigmentDESS
Immunohistochemical stainings against the transcriptional
factors SOX10 (Fig. 3) and MITF (Fig. 4) were used to
determine the expression of these two melanocyte markers
in pigmentDESS 15 weeks after transplantation.
SOX10 is expressed in the nuclei of melanocytes in the
basal layer of the epidermis in light (Fig. 3a, black arrows)
and dark (Fig. 3b, black arrows) pigmentDESS. MITF
expression was also detected in the nuclei of melanocytes
in the basal layer of the epidermis in light (Fig. 4a, black
arrows) and dark (Fig. 4b, black arrows) pigmentDESS.
Discussion
In our experimental study, we investigated if dermo-epi-
dermal skin substitutes containing melanocytes that were
transplanted express melanocyte-specific markers in the
long run (15 weeks after transplantation). In general, we
observed a similar pattern of marker expression in these
pigmentDESS as in normal human skin. Several aspects of
our findings deserve a detailed comment.
We have previously shown that we can tissue engineer
human light and dark dermo-epidermal skin substitutes
with a color that is almost identical to one of the donor
skins independently of the used melanocyte:keratinocyte
ratio [9]. Here, we used the described physiological
melanocyte:keratinocyte ratio of about 1:5 in the basal
layer of the epidermis to prepare the light or dark pig-
mentDESS that were then transplanted [16–18].
Fig. 3 Expression of SOX10 in pigmentDESS 15 weeks after transplantation. a SOX10 staining in light pigmentDESS and b staining in dark
pigmentDESS. SOX10 expression is restricted to melanocytes in the basal layer of the epidermis (black arrows). Scale bars 50 lm
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First, we investigated the presence of a well-described
anti-apoptotic cell marker, namely BCL2. BCL2 is one of
the major members of the BCL2 family of anti-apoptotic
proteins that includes also BCL-xL and MCL-1 [19]. These
proteins are generally situated in the outer mitochondrial
membrane in the cells. There they bind and inhibit the pro-
apoptotic members of the BCL2 family as, e.g., BAK and
BAX, so preserving the outer mitochondrial membrane
stability and preventing cell apoptosis by circumventing
the intrinsic apoptotic pathway [20]. Studies describe the
presence of BCL2 in fetal and adult human skin, with a
higher level of BCL2 protein expression in melanocytes
than in keratinocytes [21–23]. This higher level of BCL2 in
melanocytes is thought to impede UV irradiation-induced
apoptosis, whereas keratinocytes which contain less BCL2
are more susceptible for apoptosis already at low doses of
UV irradiation [24].
We observed the presence of BCL2 in melanocytes of
pigmentDESS 14 weeks after transplantation basically
reflecting the physiological situation of normal human skin.
This suggests that these melanocytes are physiologically
functioning and might efficiently protect against solar
radiation which is of pivotal importance, once pigment-
DESS are applied clinically.
Second, we analyzed the expression of the transcription
factors SOX9 and SOX10 in pigmentDESS melanocytes.
Lately, it was observed that SOX9 drives the transition of
undifferentiated melanoblasts to differentiated melano-
cytes in postnatal skin eventually resulting in melano-
genesis, i.e., the production of melanin [25–27]. SOX10
is a widely described transcription factor and one of the
most important regulators of embryonic melanocyte
development and of maintenance of melanocyte stem cells
in hair follicle bulge in postnatal skin [28, 29]. Further-
more, SOX10 is expressed in postnatal melanocytes of the
epidermal basal layer, keeping them in a more undiffer-
entiated state [30]. Both SOX9 and SOX10 activate the
expression of the transcription factor MITF [31]. MITF
itself is a well-characterized master regulator of melano-
cyte survival and melanogenesis, thereby regulating the
expression of tyrosinase (Tyr), tyrosinase-related protein 1
(Tyrp1), and 2 (Tyrp2) that is crucial for melanin synthesis
[32, 33].
In our pigmentDESS, we observed the presence of
SOX9 in melanocytes in the basal layer of the epidermis
and, moreover, also some SOX10 positive melanocytes. As
MITF expression is activated by SOX9 and 10, the pre-
sence of MITF in melanocytes of our transplanted pig-
mentDESS does not surprise. It demonstrates that another
functional pathway, namely the induction of MITF by
SOX9 and 10 seems to work in a physiological way.
Taken together, our molecular findings regarding
expression of transcription factors regulating melanocyte
differentiation and melanogenesis (the pigment production)
are in line with our previous macroscopic observations that
transplanted light and dark pigmentDESS display the same
color as the donor skin color [9].
One could speculate that, because of the presence of
SOX10, undifferentiated melanocytes, even melanocyte
precursor cells, are residing in the epidermis of our pig-
mentDESS. This leads to the assumption that not only
15 weeks after transplantation but also for an indefinite
longer time, melanocyte precursors (that give rise to mel-
anocytes) could be maintained in our dermo-epidermal skin
Fig. 4 Expression of MITF in pigmentDESS 15 weeks after transplantation. a MITF staining in light pigmentDESS and b staining in dark
pigmentDESS. MITF expression is restricted to melanocytes in the basal layer of the epidermis (black arrows). Scale bars 50 lm
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substitutes, which is again of clinical importance, as we
want to produce pigmentDESS that guarantee the patients’
skin color for life.
In future studies, we could use our model to analyze the
impact of UV light onto pigmentDESS, and look at the
presence and change of marker expressions after UV irra-
diation. It was described previously that BCL2 was
upregulated in melanocytes through MITF activation after
UV irradiation and thereby enhancing melanocyte survival
[23, 24]. In addition, human melanocytes isolated and
grown in vitro upregulated SOX9 after UV irradiation and
increased their melanin production [26].
In conclusion, we observed that our pigmentDESS
express typical melanocyte survival, differentiation, and
melanogenesis markers 15 weeks after transplantation.
These findings have significant implications regarding the
envisioned clinical application.
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